Published in BMJ on July 19, 2012
Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev (2013) 2.43
Modified Ham test for atypical hemolytic uremic syndrome. Blood (2015) 1.52
Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int (2016) 1.39
Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol (2012) 1.36
Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol (2014) 1.22
Isolation facilities for highly infectious diseases in Europe--a cross-sectional analysis in 16 countries. PLoS One (2014) 1.16
Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) (2012) 1.10
Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol (2013) 0.93
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012. MAbs (2013) 0.93
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev (2014) 0.91
Development of monoclonal antibodies and immunoassays for sensitive and specific detection of Shiga toxin Stx2f. PLoS One (2013) 0.88
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) (2015) 0.87
(S)-N-Methyldihydroquinazolinones are the Active Enantiomers of Retro-2 Derived Compounds against Toxins. ACS Med Chem Lett (2013) 0.87
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol (2014) 0.86
New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence (2013) 0.84
Treating Shiga toxin induced haemolytic uraemic syndrome. BMJ (2012) 0.84
Modulation of the enterohemorrhagic E. coli virulence program through the human gastrointestinal tract. Virulence (2013) 0.83
Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant (2013) 0.83
Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge. Emerg Infect Dis (2016) 0.83
Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Blood (2013) 0.82
Management of hemolytic uremic syndrome. F1000Prime Rep (2014) 0.82
Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrol Dial Transplant (2012) 0.81
Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol (2012) 0.81
Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol (2013) 0.81
Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype. Front Cell Infect Microbiol (2015) 0.80
Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota. Appl Environ Microbiol (2012) 0.80
Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis (2014) 0.79
Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity. Nat Rev Nephrol (2012) 0.79
Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence. Infect Dis Clin North Am (2013) 0.78
Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun (2013) 0.78
Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. J Clin Exp Nephrol (2016) 0.77
Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice. Clin Vaccine Immunol (2015) 0.77
Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome. BMC Res Notes (2014) 0.77
Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol (2013) 0.76
Autoimmunity: homeostasis of innate immunity gone awry. J Clin Immunol (2012) 0.76
Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection. PLoS One (2013) 0.76
Characteristics of clinical Shiga toxin-producing Escherichia coli isolated from British Columbia. Biomed Res Int (2013) 0.76
Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol (2017) 0.75
Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol (2016) 0.75
Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection. PLoS One (2013) 0.75
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci (2016) 0.75
Microbes without frontiers: severe haemolytic-uraemic syndrome due to E coli O104:H4. BMJ Case Rep (2012) 0.75
Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference. Ann Intensive Care (2017) 0.75
Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4. Mediators Inflamm (2015) 0.75
[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease]. Pathologe (2014) 0.75
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J (2017) 0.75
Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol (2014) 0.75
Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr (2017) 0.75
Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet (2005) 9.78
Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med (2011) 9.37
Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med (2011) 8.55
Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis (2011) 8.25
The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med (2000) 7.78
Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med (2011) 7.11
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One (2011) 6.75
A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA (1994) 4.85
Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet (2011) 4.70
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis (2000) 4.24
Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher (2010) 3.47
Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med (2011) 3.28
Escherichia coli O157. Lancet (2010) 2.96
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain (2012) 2.49
The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis (2001) 2.47
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med (2002) 2.00
Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother (2012) 1.62
Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr (2009) 1.61
Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.36
Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis (2002) 1.36
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood (2011) 1.23
The 2011 Shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticity. Clin Microbiol Infect (2011) 0.98
Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents (2010) 0.96
A German outbreak of haemolytic uraemic syndrome. Lancet (2011) 0.96
Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol (2011) 0.93
Monitoring patients in the community with suspected Escherichia coli O157 infection during a large outbreak in Scotland in 1996. Epidemiol Infect (2001) 0.93
Steroids in the hemolytic uremic syndrome. Pediatr Nephrol (1998) 0.92
Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects. Ther Apher Dial (2011) 0.89
[Clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as in-patients]. Dtsch Med Wochenschr (2011) 0.86
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 9.00
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science (2008) 6.66
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation (2006) 5.99
Microbial exposure during early life has persistent effects on natural killer T cell function. Science (2012) 5.90
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes (2006) 5.29
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Atenolol in hypertension: is it a wise choice? Lancet (2004) 4.75
PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet (2006) 4.72
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 4.20
Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation (2005) 4.20
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut (2013) 4.07
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A (2009) 4.02
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96
Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol (2007) 3.96
On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet (2008) 3.95
Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Nod2 is essential for temporal development of intestinal microbial communities. Gut (2011) 3.69
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med (2004) 3.63
Renin-angiotensin system and cardiovascular risk. Lancet (2007) 3.47
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet (2010) 3.39
A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology (2007) 3.37
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Short-term sleep loss decreases physical activity under free-living conditions but does not increase food intake under time-deprived laboratory conditions in healthy men. Am J Clin Nutr (2009) 3.20
Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet (2004) 3.19
A comprehensive evaluation of SNP genotype imputation. Hum Genet (2008) 3.18
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14